Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Trial details
- Registry ID
- NCT04016805
- Phase
- Phase 2
The FDA approved Ibrutinib (Imbruvica) on 13 Nov 2013.
Drug identity checked against registry records
Also recorded as Imbruvica
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805 | TGTX | Phase 2 | Terminated | 2022-05-22Actual |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)NCT03328078 | CRIS | Phase 1, Phase 2 | Recruiting | 2027-07Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2013-11-13Day | Ibrutinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA205552", "applicant_as_listed_by_fda": "PHARMACYCLICS LLC", "brand_names": ["IMBRUVICA"], "active_ingredients": ["IBRUTINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20131113", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |